RESEARKA

Several methodological questions bear on the interpretation of the PCSK9 inhibitors longevity evidence base for longevity-relevant outcomes. A fundamental concern is the reliance on surrogate endpoints such as LDL-C reduction and composite cardiovascular events rather than all-cause mortality or healthspan measures, which introduces uncertainty about whether biomarker improvements translate to meaningful longevity gains (Ioannidis 2005). Substantial heterogeneity exists across trials in populations studied, baseline cardiovascular risk, treatment durations, and concurrent interventions including statin intensity, complicating pooled effect estimation (Bruggen 2024). The tension between mechanistic plausibility—supported by preclinical observations of anti-inflammatory and endothelial-protective effects—and the mixed clinical mortality data (Ma 2025; Steg 2019; Wang 2022b) underscores the mechanism-to-clinic translation gap. Future investigations would benefit from longer treatment durations, aging-specific endpoints such as functional status and multimorbidity progression, and explicit assessment of concurrent lifestyle or pharmacological interventions that may modify PCSK9 inhibitors longevity effects.

Citation Support

• source_1 Ma 2025
• source_2 Schwartz 2021
• source_3 Lehrke 2024
• source_4 Imran 2023
• source_5 Faraidy 2023